'We intend to challenge this approval and licensure. We do not believe that this approval will significantly affect the trajectory of the pandemic, as we know that these shots are less than 50% effective against the variant in circulation now.'
Now that COVID vaccines have established mRNA technology as the 'new frontier for vaccine development,' pharma giants have set their sights on an mRNA vaccine for respiratory syncytial virus (RSV) — which they hope to add to an already overburdened childhood vaccine schedule.
The lawsuit alleges, among other things, that Rutgers is working with Pfizer, Moderna and Johnson & Johnson to study and develop their vaccines in on-going clinical trials, and will benefit financially if more people are required to take the shots.
In a new research paper published in the journal Toxicology Reports, author Neil Z. Miller found that out of a total of 2,605 infant deaths reported to VAERS between 1990 and 2019, 58% occurred within three days of vaccination, and 78% occurred within seven days of vaccination.